RYTM Yann Mazabraud sells $439K worth of shares
May 02, 2025, 10:36 AM
0.00%
What does RYTM do
Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
Yann Mazabraud sold 6,745 shares of RYTM on 29 April at $65.08 per share, worth a total of $439K. They now own 37,655 RYTM shares, or a 15% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.